Press Release

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:

  • Morgan Stanley 21st Annual Global Healthcare Conference (New York, New York)
    • Monday, September 11, 2023 at 4:55 p.m. ET, fireside chat
  • H.C. Wainwright 25th Annual Global Investment Conference (New York, New York)
    • Tuesday, September 12, 2023 at 2:30 p.m. ET, corporate presentation
  • Cantor Global Healthcare Conference (New York, New York)
    • Thursday, September 28, 2023 at 8:35 a.m. ET, fireside chat

Webcasts will be available on the “Events & Presentations” page within the Investors section of the Alector website at Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About Alector

Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit

Alector Contacts:

Katie Hogan

1AB (media)
Dan Budwick

Argot Partners (investors)
Laura Perry

Primary Logo

Source: Alector, Inc.